Phathom Q2 Revenue Nearly Doubles, Loss Narrows Sharply; Cash Runway Extended
PHAT sits 42% above its 52-week low of $8.025.
Summary
Phathom Pharmaceuticals reported Q2 2026 revenue of $74.3M, nearly double the prior year, and a sharply narrower net loss of $17.6M. Cash reserves grew to $182.5M, and management confirmed a 12-month runway. The Phase 2 EoE trial completed enrollment early, with data due in Q4.
Key Events · Earnings and Guidance · PHAT
-
Revenue Nearly Doubles
Q2 2026 product revenue reached $74.3M, up 88% from $39.5M in Q2 2025. Six-month revenue of $132.6M nearly matched full-year 2025 revenue of $150M+.
-
Net Loss Narrows Sharply
Net loss improved to $17.6M in Q2 2026 from $75.8M a year ago, driven by revenue growth and a $30M reduction in SG&A expenses, including a $23M cut in advertising and promotion.
-
Cash Runway Extended
Cash and equivalents rose to $182.5M at June 30, 2026, from $130.0M at year-end 2025, following a $122M equity raise and debt refinancing. Management states sufficient capital for at least the next 12 months.
-
Phase 2 EoE Trial Enrollment Complete
The Phase 2 pHalcon-EoE-201 trial enrolled 95 patients ahead of schedule. Topline results from the 12-week blinded portion are expected in Q4 2026, potentially opening a new indication for vonoprazan.
Analysis · PHAT · Life Sciences
Phathom's second-quarter results mark a dramatic improvement in its financial trajectory. Product revenue nearly doubled year-over-year to $74.3 million, while the net loss shrank from $75.8 million to $17.6 million — a combination of strong commercial execution and a steep drop in operating expenses following last year's restructuring. The company ended the quarter with $182.5 million in cash, up from $130 million at year-end, after completing a $122 million equity raise and refinancing its debt. Management explicitly states it has enough capital to fund operations for at least the next twelve months, removing near-term liquidity concerns. The Phase 2 EoE trial also enrolled ahead of schedule, with topline data expected in Q4 2026 — a potential catalyst that could expand the vonoprazan franchise beyond GERD and H. pylori.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAT was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $928.4M. The 52-week trading range was $8.03 to $18.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.